These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 30593409)

  • 1. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis.
    van der Graaff D; Kwanten WJ; Francque SM
    Med Hypotheses; 2019 Jan; 122():188-197. PubMed ID: 30593409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD.
    van der Graaff D; Chotkoe S; De Winter B; De Man J; Casteleyn C; Timmermans JP; Pintelon I; Vonghia L; Kwanten WJ; Francque S
    JHEP Rep; 2022 Feb; 4(2):100412. PubMed ID: 35036886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nocturnal hypoxia-induced oxidative stress promotes progression of pediatric non-alcoholic fatty liver disease.
    Sundaram SS; Halbower A; Pan Z; Robbins K; Capocelli KE; Klawitter J; Shearn CT; Sokol RJ
    J Hepatol; 2016 Sep; 65(3):560-9. PubMed ID: 27501738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
    Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
    Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
    Tana C; Tana M; Rossi S; Silingardi M; Schiavone C
    J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats.
    Van der Graaff D; Kwanten WJ; Couturier FJ; Govaerts JS; Verlinden W; Brosius I; D'Hondt M; Driessen A; De Winter BY; De Man JG; Michielsen PP; Francque SM
    Lab Invest; 2018 Oct; 98(10):1263-1275. PubMed ID: 29326427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
    Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
    J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.
    Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL
    J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental models of non-alcoholic fatty liver disease in rats.
    Kucera O; Cervinkova Z
    World J Gastroenterol; 2014 Jul; 20(26):8364-76. PubMed ID: 25024595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic intermittent hypoxia promotes early intrahepatic endothelial impairment in rats with nonalcoholic fatty liver disease.
    Hernández-Bustabad A; Morales-Arraez D; González-Paredes FJ; Abrante B; Díaz-Flores F; Abreu-González P; de la Barreda R; Quintero E; Hernández-Guerra M
    Am J Physiol Gastrointest Liver Physiol; 2022 Oct; 323(4):G362-G374. PubMed ID: 35916415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of Cyclooxygenase End Products and Oxidative Stress to Intrahepatic Endothelial Dysfunction in Early Non-Alcoholic Fatty Liver Disease.
    Gonzalez-Paredes FJ; Hernández Mesa G; Morales Arraez D; Marcelino Reyes R; Abrante B; Diaz-Flores F; Salido E; Quintero E; Hernández-Guerra M
    PLoS One; 2016; 11(5):e0156650. PubMed ID: 27227672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    Kakisaka K; Suzuki Y; Fujiwara Y; Abe T; Yonezawa M; Kuroda H; Ishida K; Sugai T; Takikawa Y
    J Gastroenterol; 2018 Dec; 53(12):1285-1291. PubMed ID: 29680867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective insulin resistance with differential expressions of IRS-1 and IRS-2 in human NAFLD livers.
    Honma M; Sawada S; Ueno Y; Murakami K; Yamada T; Gao J; Kodama S; Izumi T; Takahashi K; Tsukita S; Uno K; Imai J; Kakazu E; Kondo Y; Mizuno K; Kawagishi N; Shimosegawa T; Katagiri H
    Int J Obes (Lond); 2018 Sep; 42(9):1544-1555. PubMed ID: 29717275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.